Inventory Disclosure [Abstract]
Inventory
Inventory Disclosure [Text Block]
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities [Text Block]
The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period.
Quarterly Financial Information [Abstract]
Unaudited Quarterly Results [Abstract]
Schedule of quarterly financial information
Schedule of Quarterly Financial Information [Table Text Block]
Accounting Policies [Abstract]
Significant Accounting Policies
Significant Accounting Policies [Text Block]
Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities [Table Text Block]
Tabular disclosure of the components of accrued liabilities and other current liabilities.
Research and development
Research and Development Revenue
Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product.
Selling, general and administrative expense
Selling, General and Administrative Expense
Research and development expense
Research and Development Expense
Patent preparation fees
Patent Preparation Fees
The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property.
Litigation accrual expense
Loss Contingency, Loss in Period
Operating loss
Operating Income (Loss)
Net income (loss)
Net Income (Loss) Attributable to Parent
Earnings Per Share, Basic and Diluted
Earnings Per Share, Basic and Diluted
Schedule of Property, Plant and Equipment [Table]
Property, Plant and Equipment [Table]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Domain]
Lab equipment [Member]
Lab equipment [Member]
Long lived, depreciable assets that are used in the laboratory.
Computer Equipment [Member]
Computer Equipment [Member]
Furniture and Fixtures [Member]
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life
Property, Plant and Equipment, Useful Life
Receivables percentage
Receivables Percentage
Percentage of accounts receivables represented from National Institutes of Health and BARDA.
Document and Entity Information [Abstract]
Document and Entity Information [Abstract]
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Filer Category
Entity Filer Category
Trading Symbol
Trading Symbol
Document Type
Document Type
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Amendment Flag
Amendment Flag
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Current Reporting Status
Entity Current Reporting Status
Entity Public Float
Entity Public Float
Commitments and Contingencies Disclosure [Abstract]
Loss Contingencies [Table]
Loss Contingencies [Table]
Litigation Case [Axis]
Litigation Case [Axis]
Litigation Case Type [Domain]
Litigation Case [Domain]
License Agreement litigation
License Agreement Litigation [Member]
License Agreement Litigation [Member]
Litigation Status [Axis]
Litigation Status [Axis]
Litigation Status [Domain]
Litigation Status [Domain]
Pending litigation
Pending Litigation [Member]
Loss Contingency Nature [Axis]
Loss Contingency Nature [Axis]
Loss Contingency, Nature [Domain]
Loss Contingency, Nature [Domain]
Surety bond
Surety Bond [Member]
Balance Sheet Location [Axis]
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Balance Sheet Location [Domain]
Other assets
Other Assets [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Percentage of net profits from sales after net profit threshold
Percentage of Net Profits from Sales After Net Profit Milestone Resulting From Award Damages
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale.
Net profit threshold
Net Profit Milestone
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale
Equitable payment stream following first commercial sale, duration
Duration of Equitable Payment Stream Following First Commercial Sale
The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale.
Percentage of litigation costs awarded
Litigation Costs Awarded, Percentage
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses.
Plaintiff attorneys' fee and expenses
Amount Plaintiff May Recover
The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses.
Payment to post collateral for surety bond
Payment to Post Collateral for Surety Bond
Payment to post collateral for surety bond.
Collateral
Collateral
Percentage of cash collateral for surety bond.
Surety bond
Surety bond
Amount of surety bond.
Liabilities subject to compromise, loss contingency legal fees
Liabilities subject to compromise, loss contingency legal fees
The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise.
Final order and judgment
Final Order And Judgment
Final order and judgment entered by the Court awarding damages to the Plaintiff.
Loss contingency, accrual
Loss Contingency Accrual
Final order and judgment pre and post-judgment Interest
Final Order And Judgment Pre and Post-Judgment Interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre and post-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Final order and judgment including interest
Final order and judgment plus interest
Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff.
Final order and judgment post-judgment interest
Final Order And Judgment Post-Judgment Interest
Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff.
Statement of Cash Flows [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]
Cash flows from operating activities:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Adjustments to reconcile net income (loss) to net cash used in operating activities
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and other amortization
Depreciation, Depletion and Amortization
Increase (decrease) in fair value of warrants
Increase In Fair Value Of Warrants
Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock.
Stock-based compensation
Share-based Compensation
Gain on sale of assets
Gain (Loss) on Disposition of Assets
Loss on disposal of assets
Loss On Disposal Of Assets
Amount of loss on disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
Non-cash interest expense
Other Noncash Expense
Changes in assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Inventory
Increase (Decrease) in Inventories
Deferred costs
Increase (Decrease) in Deferred Charges
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense
Other assets
Increase (Decrease) in Other Operating Assets
Deferred income taxes, net
Deferred Income Tax Expense (Benefit)
Accounts payable, accrued expenses and other current liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Liabilities subject to compromise
Liabilities Subject to Compromise, Period Increase (Decrease)
Deferred revenue
Increase (Decrease) in Deferred Revenue
Other liabilities
Increase (Decrease) in Other Operating Liabilities
Net cash provided by (used in) operating activities
Net Cash Provided by (Used in) Operating Activities
Cash flows from investing activities:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Capital expenditures
Payments to Acquire Property, Plant, and Equipment
Proceeds from sale of assets
Proceeds from Sale of Productive Assets
Restricted Cash
Payments for (Proceeds from) Other Investing Activities
Net cash (used in) provided by investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Net proceeds from exercise of warrants and options
Proceeds From Issuance Of Warrants and Options
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Payment of common stock tendered for employee tax obligations
Payments Related to Tax Withholding for Share-based Compensation
Proceeds from issuance of long-term debt
Proceeds from Issuance of Long-term Debt
Repayments of long-term debt
Repayments of Long-term Debt
Change in excess tax benefit stock-based compensation, financing activities
Change In Excess Tax Benefit Stock-Based Compensation, Financing Activities
Amount of cash inflow/(outflow) from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of period
Cash and Cash Equivalents, at Carrying Value
Cash and cash equivalents at end of period
Supplemental disclosure of non-cash financing activities:
Supplemental Cash Flow Information [Abstract]
Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise
Reclass of Common Stock Warrant Liability To Additional Paid In Capital Upon Exercise
Value of reclass of common stock warrant liability to additional paid-in capital upon exercise in noncash financing activities.
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Equity Components [Axis]
Equity Components [Axis]
Equity Component [Domain]
Equity Component [Domain]
Performance Shares [Member]
Performance Shares [Member]
Award Type [Axis]
Award Type [Axis]
Award Type [Domain]
Equity Award [Domain]
Stock Options
Employee Stock Option [Member]
Range [Axis]
Range [Axis]
Range [Domain]
Range [Domain]
Minimum [Member]
Minimum [Member]
Maximum [Member]
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Stock-based compensation expense
Allocated Share-based Compensation Expense
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Number of shares granted
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Number of shares exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Number of shares canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Number of shares outstanding at end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding at beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price, granted
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Weighted average exercise price, exercised
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted average exercise price, canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Weighted average exercise price outstanding at end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining life, outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Intrinsic value, outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Number of shares vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Weighted average exercise price, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Weighted average remaining life, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Intrinsic value, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Number of shares exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Weighted average exercise price, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Weighted average remaining life, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Intrinsic value, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Unrecognized stock-based compensation cost, net of estimated forfeitures
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Weighted average remaining requisite service period (in years)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Fair value of vested stock options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Total intrinsic value of stock options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Performance-based stock options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Performance Based, Number
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date subject to performance conditions under the option plan.
Performance-based stock options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options Exercisable, Performance Based, Number
The number of shares exercisable as of the balance sheet date related to performance conditions met under the option plan.
Statement of Financial Position [Abstract]
ASSETS
Assets [Abstract]
Cash and cash equivalents
Restricted cash
Restricted Cash and Cash Equivalents, Noncurrent
Accounts receivable
Accounts Receivable, Net, Current
Inventory
Inventory, Net
Prepaid expense and other assets, current
Prepaid Expense and Other Assets, Current
Total current assets
Assets, Current
Property, plant and equipment, net
Property, Plant and Equipment, Net
Deferred costs
Deferred Costs, Noncurrent
Goodwill
Goodwill
Other assets
Other Assets, Noncurrent
Total assets
Assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Liabilities and Equity [Abstract]
Accounts payable
Accounts Payable, Current
Accrued expenses and other current liabilities
Accrued Liabilities, Current
Long-term debt, current maturities
Long-term Debt, Current Maturities
Total current liabilities
Liabilities, Current
Deferred revenue
Deferred Revenue, Noncurrent
Deferred income tax liability
Deferred Tax Liabilities, Net, Noncurrent
Other liabilities
Other Liabilities
Liabilities subject to compromise
Liabilities Subject to Compromise
Total liabilities
Liabilities
Stockholders' equity
Stockholders' Equity Attributable to Parent [Abstract]
Common stock ($.0001 par value, 100,000,000 shares authorized, 54,114,296 and 53,504,296 issued and outstanding at December 31, 2015, and December 31, 2014, respectively
Common Stock, Value, Issued
Additional paid-in capital
Additional Paid in Capital, Common Stock
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Total stockholders' equity
Stockholders' Equity Attributable to Parent
Total liabilities and stockholders' equity
Liabilities and Equity
Equity [Abstract]
Class of Warrant or Right [Table]
Class of Warrant or Right [Table]
Measurement Frequency [Axis]
Measurement Frequency [Axis]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value, Measurements, Recurring [Member]
Fair Value, Hierarchy [Axis]
Fair Value, Hierarchy [Axis]
Fair Value, Measurements, Fair Value Hierarchy [Domain]
Fair Value Hierarchy [Domain]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Scenario [Axis]
Scenario [Axis]
Scenario, Unspecified [Domain]
Scenario, Unspecified [Domain]
Extended Expiration Period [Member]
Extended Expiration Period [Member]
Extended Expiration Period [Member]
Related Party [Axis]
Related Party [Axis]
Related Party [Domain]
Related Party [Domain]
Affiliated Entity
Affiliated Entity [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right [Line Items]
Capital units, authorized
Capital Units, Authorized
Common stock, shares authorized
Common Stock, Shares Authorized
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Change In fair value of common stock warrants
Change In Fair Value Of Common Stock Warrants
The aggregate adjustment to the fair market value of liability classified warrants to purchase common stock.
Warrants to purchase common stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Exercise price of warrants to purchase common stock
Class of Warrant or Right, Exercise Price of Warrants or Rights
Warrants contractual term (in years)
Warrants contractrual term
The contractual life of warrants.
Commitment to Invest
Commitment to Invest
Related party commitment to invest at the Company's discretion in exhange for common stock and warrants.
Service Agreement Term
Service Agreement Term 1
Service agreement, entered into with MacAndrews & Forbes LLC ("M&F"), in years.
Warrants to purchase percentage of acquired shares
Warrants to Purchase Percentage of Shares
Related party commitment to invest at the Company's discretion in exhange for warrants to purchase a percentage of the number of Company shares acquired by the related party.
Proceeds from issuance of warrants and options
Proceeds From Issuance Of Warrants and Options 1
The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.
Common stock, shares issued
Common Stock, Shares, Issued
Expense of Warrants Held as Assets
Expense of Warrants Held as Assets
The expense associated with warrants held as assets.
Organization and Basis of Presentation [Abstract]
Organization and Basis of Presentation [Abstract]
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event Type [Axis]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event [Member]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Bankruptcy claims, number of claims outstanding
Bankruptcy Claims, Number Of Claims Outstanding
The aggregate number of claims outstanding with the bankruptcy court.
Payment to extend days to satisfy claim
Payment To Extend Days To Satisfy Claim
Total amount of payment to PharmAthene to extend the number of days to satisfy the claim.
Amount to be paid on effective date of plan of reorganization
Amount To Be Paid On Effective Date of Plan Of Reorganization
The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization.
Bankruptcy claims, all other liquidated proof of claims
Bankruptcy claims, all other liquidated proof of claims
The total dollar value of all other liquidated proof of claims, outside of the litigation.
Proof Of Claim Asserted In Connection With Litigation
Proof Of Claim Asserted In Connection With Litigation
Proof of claim asserted in connection with litigation field with the Bankruptcy Court.
Debt satisfied
Debt Satisfied
The Company was authorized by the Bankruptcy Court to satifsy a fully-secured term loan.
Prepetition claim satisfied
Prepetition Claim Satisfied
The Company has satisfied a prepetition claim as part of the assumption of the Commercial Manufacturing Agreement, as amended, pursuant to orders of the Bankruptcy Court.
Rent reduction
Rent Reduction
The amount of reduced monthly rent for the research and development facility due to the addendum to the Commercial Lease.
Proof of claim, withdrawn
Proof of Claim, Withdrawn
Proof of claim from commercial lease for research facility, withdrawn.
Bankruptcy claims, amount of unliquidated claim
Bankruptcy claims, amount of unliquidated claim
The amount of unliquidated proof of claim filed with the Bankruptcy Court.
Net capital deficiency
Net Capital Deficiency
Net Capital Deficiency. Net capital is equal to the net worth of the broker dealer, less certain items such as exchange memberships, carrying value of securities not readily marketable, haircuts on marketable securities in proprietary accounts, furniture and equipment and other illiquid assets as defined.
Bonus
Accrued Bonuses, Current
Professional fees
Accrued Professional Fees, Current
Vacation
Accrued Vacation, Current
Other
Other Accrued Liabilities, Current
Total
Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Award vesting period
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of shares granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Number of shares vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Number of shares canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Number of shares outstanding at end of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average grant-date fair value, granted
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value, vested
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Weighted averaged grant-date fair value, canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted average grant-date fair value outstanding at end of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Unrecognized stock-based compensation cost
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options
Weighted average remaining requisite service period
Fair value of stock compensation vested
Stock Issued During Period, Value, Restricted Stock Award, Gross
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table]
Schedule of Long-term Debt Instruments [Table]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Long-term Debt, Type [Domain]
Debt Instrument [Axis]
Debt Instrument [Axis]
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Term loan
Debt, Long-term and Short-term, Combined Amount
Term loan, fixed interest rate
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate
Line of credit facility, maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Loan, period
Loan Term
Term of the loan in years.
Cash Collateral for Borrowed Securities
Cash Collateral for Borrowed Securities
Stock options activity
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
Stock appreciation rights award activity
Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block]
Restricted stock and restricted stock units activity
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Quarterly Financial Information
Quarterly Financial Information [Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities [Axis]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
Stock Appreciation Rights (SARs) [Member]
Stock Appreciation Rights (SARs) [Member]
Restricted Stock Units (RSUs)
Warrants
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Expiration period
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Maximum number of shares to be issued
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares that Could Be Issued
Share-based compensation arrangement by share-based payment award, maximum number of shares that could be issued
Number of shares exercised
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period
The number of exercises made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
Weighted average exercise price granted
Share-based Compensation Arrangement by Share-based Payment Award, Options Granted, Weighted Average Excercise Price
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of granted options under the stock option plan.
Weighted average exercise price exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options Excercised, Weighted Average Excercise Price
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of exercised options under the stock option plan.
Weighted average exercise price canceled and expired
Share-based Compensation Arrangement by Share-based Payment Award, Options Canceled / Expired, Weighted Average Excercise Price
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of canceled and expired options under the stock option plan.
Weighted average exercise price outstanding at end of period
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price
The weighted-average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Intrinsic value outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Intrinsic Value
Amount of difference between fair value of the underlying equity instruments reserved for issuance and exercise price of equity instruments outstanding.
Weighted average exercise price, vested and expected to vest
Share-based Compensation Arragement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Excercise Price
As of the balance sheet date, the weighted average excercise price for outstanding equity instruments other than options that are fully vested of expected to vest.
Weighted average remaining life, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Remaining Life
The weighted-average remaining life in years, for equity instruments other than options vested and expected to vest.
Intrinsic value, vested and expected to vest
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share
Number of shares exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other then Options, Exercisable Number
The number of shares into which fully or partially vested, other than stock (or unit) option plans outstanding as of the balance sheet date can be currently converted under the option plan.
Weighted average exercise price, exercisable
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price
Weighted average remaining life, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Remaining Life
The weighted-average remaining life in years, for excercisable equity instruments other than options.
Intrinsic value, exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Intrinsic Value
Amount of difference between fair value of the underlying equity instrument for the issuance and exercise price of vested portions of equity instruments outstanding and currently exercisable.
Fair value of vested stock appreciation rights
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Total intrinsic value of stock appreciation rights exercised
Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Exercises in Period, Intrinsic Value
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on equity, other than options exercised (or share units converted) into shares.
Balance Sheet Parenthetical [Abstract]
Balance Sheet Parenthetical [Abstract]
Common stock, par value
Common Stock, Par or Stated Value Per Share
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Income Tax Disclosure [Abstract]
Income Tax
Income Tax Disclosure [Text Block]
Research and Development [Abstract]
Procurement Contract [Table]
Procurement Contract [Table]
Procurement Contract [Table]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Axis]
Procurement Contract [Domain]
Procurement Contract [Domain]
Procurement Contract [Domain]
BARDA Contract
Barda Contract [Member]
Barda Contract [Member]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Procurement Contract [Line Items]
Number of courses to be delivered
Number of Courses To Be Delivered 1
Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile
Value of contract
Government Contract, Value of Award 1
Value of base contract award.
Contract value of manufacturing and delivery activities
Contract Value of Manufacturing and Delivery Activities
Contract value of manufacturing and delivery activities.
Contract value of development and support activities
Contract Value of Development and Support Activities
Contract value of development and support activities
Contract value of various options
Contract Value of Various Options
Contract value of various options exercisable at BARDA's discretion.
Contract value, option, FDA approval
Contract Value, Option, FDA Approval
Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion.
Contract value, detail of option exercisable, development activities
Contract Value, Detail Of Option Exercisable, Development Activities
Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion.
Contract value, detail of option exercisable, production activities
Contract Value, Detail Of Option Exercisable, Production Activities
Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion.
Number of courses under modified contract
Government Contract, Number of Courses Purchased Under Modified Contract
Government contract, number of courses to be purchased under modified contract.
Number of courses manufactured using federal funds
Government Contract, Number of Courses Manufactured Using Federal Funds
Government contract, number of courses to be delivered that were manufactured using federal funds under prior development contracts.
Proceeds from manufacture and physical delivery of course, government contractses
Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts
Proceeds from manufacture and physical delivery of courses, government contracts.
Proceeds from advance payments under the BARDA contract
Proceeds from Advance Payments, Government Contracts
Proceeds from advance payments, government contracts
Milestone payment
Milestone payment
Proceeds from milestone payment, Government contracts
Proceeds from physical delivery of courses, government contracts
Proceeds From Physical Delivery Of Courses, Government Contracts
Proceeds from physical delivery of courses, government contract.
Courses delivered
Number of courses delivered and accepted
Number of tecovirimat, also known as ST-246, courses delivered and accepted to the U.S. Strategic National Stockpile.
Government contract, number of free courses delivered and accepted
Government Contract, Number of Free Courses Delivered and Accepted
Number of courses of tecovirimat delivered and accepted to the Strategic Stockpile at no cost to the government.
Number of courses delivered and accepted at provisional dosage, once daily
Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily
Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile.
Courses delivered provisional dosage, twice daily
Courses Delivered Provisional Dosage, Twice Daily
Courses of tecovirimat delivered to the Strategic Stockpile at the provisional dosage of 600 mg twice daily (1,200 mg per day).
Contract receivable collected, delivered products
Contract Receivable Collected Delivered Products
Amount billed to customers under contracts or programs and collected for delivered product. Excludes amounts due that have been withheld because of retainage provisions in a contract.
Contract receivable collected for reimbursed R&D and supportive studies
Contract receivable collected, research and developemnt services
Amount billed to customers under long-term contracts or programs and collected for research and development services. Excludes amounts due that have been withheld because of retainage provisions in a contract.
Contract Receivable Collected, Research and Development Services Since Inception
Contract Receivable Collected, Research and Development Services Since Inception
Amount billed to customers under long-term contracts or programs and collected for research and development services, since inception. Excludes amounts due that have been withheld because of retainage provisions in a contract.
Procurement contract deferred cost, noncurrent
Procurement Contract Deferred Cost, Noncurrent
Sum of the carrying amounts of deferred costs, for only the procurement contract, that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.
Deferred revenue
Deferred Revenue, Additions
Government Contract, number of courses delivered
Government Contract, number of courses delivered
Courses of Arestvyr delivered to the Strategic Stockpile
Research and development revenue long-term contract
Research and Development Revenue Long-term Contract
Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product.
Number of active contracts
Number of Active Contracts
Number of active contracts.
Number of active grants
Number of Active Grants
Number of active grants
Potential future research and development funding
Potential Future Aggregate Research and Development Expenses
Potential future aggregate research and development funding for specific projects which includes options that may or may not be exercised at the U.S. government's discretion.
Schedule of components of income tax expense (benefit)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Schedule of deferred tax assets and liabilities
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of effective income tax rate reconciliation
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Debt
Debt Disclosure [Text Block]
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current federal tax expense (benefit)
Current Federal Tax Expense (Benefit)
Current state and local tax expense (benefit)
Current State and Local Tax Expense (Benefit)
Current income tax expense (benefit)
Current Income Tax Expense (Benefit)
Deferred federal income tax expense (benefit)
Deferred Federal Income Tax Expense (Benefit)
Deferred state and local income tax expense (Benefit)
Deferred State and Local Income Tax Expense (Benefit)
Deferred income tax expense (benefit)
Benefit from (provision for) income taxes
Income Tax Expense (Benefit)
Deferred tax assets:
Components of Deferred Tax Assets [Abstract]
Deferred tax assets, net operating losses
Deferred Tax Assets, Operating Loss Carryforwards
Deferred tax assets, capitalized research and development costs
Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Deferred tax assets, amortization of intangible assets
Deferred Tax Assets, Goodwill and Intangible Assets
Deferred tax assets, share-based compensation cost
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Deferred tax assets, property, plant and equipment
Deferred Tax Assets, Property, Plant and Equipment
Deferred tax assets, deferred income
Deferred Tax Assets, Deferred Income
Deferred tax assets, alternative minimum tax
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax
Deferred tax assets, contingencies
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies
Deferred tax assets, other
Deferred Tax Assets, Other
Deferred tax assets, gross
Deferred Tax Assets, Gross
Deferred tax assets, valuation allowance
Deferred Tax Assets, Valuation Allowance
Deferred tax assets, net of valuation allowance
Deferred Tax Assets, Net of Valuation Allowance
Deferred tax liabilities:
Components of Deferred Tax Liabilities [Abstract]
Deferred tax liabilities, goodwill
Deferred Tax Liabilities, Goodwill
Deferred tax liabilities, capitalized contract costs
Deferred Tax Liabilities, Capitalized Contract Costs
Amount of deferred tax liability attributable to taxable temporary differences from capitalized contract costs.
Deferred tax liabilities, other
Deferred Tax Liabilities, Other
Deferred Tax Liabilities, Net
Deferred Tax Liabilities, Net
Loss accrual for expectation damages
Loss Accrual, Expectation Damages
Loss accrual for expectation damages.
Valuation allowance, deferred tax asset, explanation of change
Valuation Allowance, Deferred Tax Asset, Explanation of Change
Valuation allowance, increase amount
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Federal net operating loss carryforwards
Operating Loss Carryforwards
Operating loss carryforwards, subject to limitations
Deferred Tax Assts, Operating Loss Carryforwards, Subject to Limitations
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to annual limitations.
Operating loss carryforwards from excess tax deductions on stock option activity
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
U.S. federal statutory taxes
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
State and local income taxes
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Gain (loss) from fair value of common warrants
Effective Income Tax Rate Reconciliation Loss From Fair Value of Common Warrants
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in the fair value of common warrants.
Share-based compensation cost
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent
Reorganization costs
Effective Income Tax Rate Reconciliation Loss From Reorganization Costs
The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in reorganization costs.
Other adjustments
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Change in deferred tax assets valuation allowance
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective income tax rate
Effective Income Tax Rate Reconciliation, Percent
Stock Compensation Plans
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Income Statement [Abstract]
Revenues
Revenues [Abstract]
Operating expenses
Operating Expenses [Abstract]
Selling, general and administrative
Research and development
Restructuring charges
Restructuring Charges
Total operating expenses
Operating Expenses
Operating loss
Decrease (increase) in fair value of common stock warrants
Non-cash interest expense
Interest Expense
Other income, net
Nonoperating Income (Expense)
Reorganization items, net
Reorganization Items
Loss before income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest
Benefit from (provision for) income taxes
Net and comprehensive income (loss)
Basic earnings (loss) per share
Earnings Per Share, Basic
Diluted earnings (loss) per share
Earnings Per Share, Diluted
Weighted average shares outstanding: basic
Weighted Average Number of Shares Outstanding, Basic
Weighted average shares outstanding: diluted
Weighted Average Number of Shares Outstanding, Diluted
Consolidated Statements of Changes in Stockholder's Equity [Abstract]
Consolidated Statements of Changes in Stockholder's Equity [Abstract]
Statement [Table]
Statement [Table]
Common Stock
Common Stock [Member]
Additional Paid-in Capital
Additional Paid-in Capital [Member]
Retained Earnings
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent [Member]
Statement [Line Items]
Statement [Line Items]
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Total stockholders' equity (in shares)
Total stockholders' equity
Issuance of common stock upon exercise of stock options and warrants (in shares)
Issuance of common stock upon exercise of stock options and warrants
Proceeds from Stock Options Exercised
Stock-based compensation
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)
Shares Paid for Tax Withholding for Share Based Compensation
Payment of common stock tendered for employee stock-based compensation tax obligations
Warrants issued in exchange for services recorded as other assets
Issuance of Stock and Warrants for Services or Claims
Fair value of exercised common stock warrants
Proceeds from Issuance of Warrants
Change in excess tax benefit stock-based compensation,
Total stockholders' equity (in shares)
Total stockholders' equity
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Inventory, Current [Table]
Inventory, Current [Table]
Inventory [Line Items]
Inventory [Line Items]
Number of courses delivered and accepted
Work in process
Inventory, Work in Process and Raw Materials
Finished goods
Inventory, Finished Goods, Net of Reserves
Inventory write-downs
Inventory Write-downs
Inventory write-downs included in research and development expense on the balance sheet.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Reorganization [Abstract]
Reorganization [Abstract]
Debtor Reorganization Items, Legal and Advisory Professional Fees
Debtor Reorganization Items, Legal and Advisory Professional Fees
Reorganization, Professional Fees
Reorganization, Professional Fees
Amount of reorganization items related to professional fees related to entities in bankruptcy.
Reorganization, Trustee fees
Reorganization, Trustee fees
Amount of reorganization items for trustee fees related to entities in bankruptcy.
Debtor Reorganization Items, Other Expense (Income)
Debtor Reorganization Items, Other Expense (Income)
Reorganization Items
Reorganization Payments
Reorganization Payments
The amount the Company paid for reorganization items.
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Cash, Cash Equivalents, and Short-term Investments and Marketable Securities, Policy
Cash, Cash Equivalents, and Short-term Investments [Text Block]
Concentration of Credit Risk, Policy
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Accounts Receivable, Policy
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Inventory, Policy
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment, Policy
Property, Plant and Equipment, Policy [Policy Text Block]
Liabilities Subject To Compromise, Policy
Liabilities Subject To Compromise [Policy Text Block]
[Policy Text Block] for liabilities that are subject to compromise. The Company's estimate of known or potential pre-petition claims to be resolved in connection with its chapter 11 case
Revenue Recognition, Policy
Revenue Recognition, Policy [Policy Text Block]
Research and Development Expense, Policy
Research and Development Expense, Policy [Policy Text Block]
Reorganization Items, Policy
Reorganization Items, Policy [Policy Text Block]
Reorganization Items, represent costs directly attributable to the chapter 11 case and the implementation of the plan of reorganization are expensed as incurred as reorganization items
Goodwill, Policy
Goodwill, Policy [Policy Text Block]
Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill.
Share-based Compensation, Policy
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Income Tax, Policy
Income Tax, Policy [Policy Text Block]
Net Loss Per Share, Policy
Earnings Per Share, Policy [Policy Text Block]
Fair Value of Financial Instruments, Policy
Fair Value of Financial Instruments, Policy [Policy Text Block]
Legal Contingencies, Policy
Commitments and Contingencies, Policy [Policy Text Block]
Segment Reporting, Policy
Segment Reporting, Policy [Policy Text Block]
Recent Accounting Pronouncements, Policy
New Accounting Pronouncements, Policy [Policy Text Block]
Revenue, percentage
Revenue Percentage
Percentage of revenue represented from National Institutes of Health and BARDA.
Liabilities Subject to Compromise [Abstract]
Liabilities subject to compromise
Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block]
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Liabilies subject to compromise [Table Text Block]
Liabilies subject to compromise [Table Text Block]
[Table Text Block] for Schedule of liabilities that are subject to compromise.
Reorganization items [Table Text Block]
Reorganization items [Table Text Block]
The schedule represents a summary of reorganization items.
Leasehold improvements, gross
Leasehold Improvements, Gross
Computer equipment, gross
Computer Equipment
The gross amount of capitalized computer equipment costs as of the balance sheet date.
Furniture and fixtures, gross
Furniture and Fixtures, Gross
Property, plant and equipment, gross
Property, Plant and Equipment, Gross
Accumulated depreciation, depletion and amortization, property, plant, and equipment
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Property, plant and equipment, net
Depreciation and other amortization
Loss on disposal of assets
Net book value of equipment sold
Property, Plant and Equipment, Disposals
Proceeds from sale of equipment
Proceeds from Sale of Property, Plant, and Equipment
Gain on sale of equipment
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Rent expense
Rent expense Facilities Lease
Rental expense incurred for facilities leased.
Operating leases, future minimum payments due, next twelve months
Operating Leases, Future Minimum Payments Due, Next Twelve Months
Operating leases, future minimum payments, due in two years
Operating Leases, Future Minimum Payments, Due in Two Years
Operating leases, future minimum payments, due in three years
Operating Leases, Future Minimum Payments, Due in Three Years
Operating leases, future minimum payments, due in four years
Operating Leases, Future Minimum Payments, Due in Four Years
Operating leases, future minimum payments, due in five years
Operating Leases, Future Minimum Payments, Due in Five Years
Operating leases, future minimum payments due
Operating Leases, Future Minimum Payments Due
Deferred revenue
Liabilities subject to compromise, deferred revenue
The amount of pre-petition deferred revenue included in liabilities subject to compromise.
Accounts payable - pre-petition
Liabilities subject to compromise, accounts payable
The amount of pre-petition trade accounts payable included in liabilities subject to compromise.
Expectation damages accrual- PharmAthene Litigation
Legal and expert fees accrual - PharmAthene Litigation
Liabilities subject to compromise, other accrued expense
The amount of pre-petition accrued expense included in liabilities subject to compromise.
Legal and expert fees accrual - PharmAthene Litigation
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Procurement Contract and Research Agreements
Procurement Contract and Research Agreements [Text Block]
The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities.
Schedule of Related Party Transactions, by Related Party [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Member of Board of Directors
Management [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
Free rent period
Free Rent Period
Free Rent Period in months allowed under the sublease.
Monthly rental payments first five years
Monthly Rental Payments First Five Years
The amount of the monthly rental payments due under the sublease entered into for the first five years.
Initial rent period
Initial Rent Period
Represents the number of years for the initial rent period of five years and related monthly payments.
Monthly rental payments after five years
Monthly Rental Payments After Five Years
The amount of the monthly rental payments due under the sublease entered into after the first five years.
Rent period after first five years
Rent Period After First Five Years
Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase.
Legal fees
Legal Fees
Accounts payable to related party
Accounts Payable, Related Parties
Schedule of Future Minimum Rental Payments for Operating Leases
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Inventory [Abstract]
Inventory [Abstract]
Inventory
Schedule of Inventory, Current [Table Text Block]
Stockholders' Equity
Stockholders' Equity Note Disclosure [Text Block]